ICYMI, this week we had stories about new study data on roflumilast foam for scalp and body psoriasis, dupilumab's FDA approval, the future of basal cell carcinoma treatment, and more.
Click here to answer this week's poll.
This week's edition of the Mainstream Patient features stories about the best sunscreens for fall, Botox for excessive sweating, Brad Pitt's entrance into the skin care industry, and more.
Arcutis Biotherapeutics announced positive results from the ARRECTOR phase 3 trial.
Recent study results demonstrated a noticeable reduction in itch just 12 hours after application of ruxolitinib.
A recent review article lists six other JAK inhibitors that might be used as treatments for vitiligo in addition to ruxolitinib, the active ingredient in recently approved Opzelura.
Don’t click on links or attachments unless you’re sure they are legitimate.
Pulse Biosciences' new technology will treat sebaceous hyperplasia patients with Fitzpatrick skin types I-III.
In this week’s Pointers with Dr Portela, the 208SkinDoc discusses common skin conditions related to polycystic ovary syndrome.
Expert dermatologists discuss challenges in diagnosing a patient with PsA.
Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, provide tips to overcome diagnostic delay in psoriasis.
Sanofi and Regeneron’s dupliumab will provide relief to patients with extreme itch and skin lesions.
New research finds psoriasis drug apremilast could help patients lose weight.
Thorough history taking is essential during the consultation and can help clinicians rule out other potential differential diagnoses.
The search for the causes of vitiligo continues. The findings in this study stand in contrast to another one conducted in eastern China that showed a high percentage of children with vitiligo had thyroid abnormalities.
Expert dermatologists discuss future directions for the management of basal cell carcinoma.
Sherrif F. Ibrahim, MD, PhD, presents the case of a 49-year-old White woman with neglected large basal cell carcinoma.
Sherrif F. Ibrahim, MD, PhD, and Vishal Patel, MD, FAAD, FACMS, provide initial impressions of the case and discuss the use of immune checkpoint inhibitors.
Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are trending for the month of September.